Abbott details 3,000 job cuts
This article was originally published in Scrip
Executive Summary
Abbott has become the latest big pharma firm to slash its staff numbers, axing 3,000 jobs primarily in Europe, following an assessment of Solvay's R&D portfolio, which it acquired for $6.2 billion in February.